The company is headquartered in Pittsburgh, Pennsylvania and currently employs 3 full-time employees. NBSE is down -$0.36 from the previous closing price of $6.46 on volume of 224,105 shares. NBSE. Stay Competitive With Stock Market Updates! PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $5.00 per share. The current P/S ratio for NeuBase Therapeutics as of May 21, 2021 is . The trading starts at $8.72 and closed at $8.62 throughout the day. NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision … NeuBase Therapeutics share dividends. The Average True Range (ATR) for NeuBase Therapeutics Inc. is set at 0.44 The Price to Book ratio for the last quarter was 5.25, with the Price to Cash per share for the same quarter was set at 1.21. PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $5.00 per share. PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock (inclusive of 1,200,000 shares that were sold … According to Zacks, “NeuBase Therapeutics Inc. is a biotechnology company. Only 24.00% of the stock of NeuBase Therapeutics is held by insiders. Institutional Buying and Selling by … Signal Type Signal Value Data; Score -1.948 2 days ( -4.31 % ) Last Price $6.03 -4.13 % High/ Low $5.98 - $6.39 13.71% Chg 7 Days ... Best predictor for any stock is listed at the stock pages. According to TipRanks.com, Nakae is a 5-star analyst with an average return of 22.7% and a 43.8% success rate. The 1-year high price for the company’s stock is recorded $12.89 on 02/10/21, with the lowest value was $5.42 for the same time period, recorded on 04/22/21. SEC Filings (Institutional Ownership Changes) for NeuBase Therapeutics (NASDAQ:NBSE) 28.98% of NeuBase Therapeutics stock is owned by institutions. Further, NeuBase Therapeutics, Inc. (NBSE) has a beta value of 0.04, and an average true range (ATR) of 0.49. NeuBase Therapeutics overview. Wall Street analysts have given NeuBase Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Exercise of Option . NeuBase Therapeutics, Inc. (NASDAQ:NBSE) has seen a decrease in hedge fund sentiment lately. Research Neubase Therapeutics Inc stock. It is engaged in developing antisense therapies to address genetic diseases. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The company has a Price to Book ratio of 7.12. So take a peek at this free list of growing companies with insider buying. NeuBase Therapeutics General Information Description. NeuBase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. The firm set its price target to $14 (in line with other Street targets), implying $122 upside from today's close. Check the real-time NBSE stock price on the NASDAQ exchange and access historical data for NeuBase Therapeutics, Inc. stock. The young Pittsburgh-based biotech firm intends to use the … NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. Real-time exchange rate quote of Neubase Therapeutics Inc. - Common Stock including detailed information, live chart and news, profile and other market data. During the last session, NeuBase Therapeutics, Inc. (NASDAQ:NBSE)’s traded shares were 1,063,111, with the beta value of the company hitting 0.01. The company’s stock has been forecasted to trade at an average price of $16.8 over the course of the next 52 weeks, with a low of $15 and a high of $18. NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. NeuBase Therapeutics, Inc. Common Stock, also called NeuBase Therapeutics, is a biotechnology company. Their average twelve-month price target is $17.33, predicting that the stock has a possible upside of 245.97%. NeuBase Therapeutics, Inc. Common Stock (NBSE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The company’s proprietary platform includes … The average NeuBase Therapeutics stock price prediction forecasts a potential downside of N/A from the current NBSE share price of $6.70. News for NeuBase Therapeutics Inc. Thursday, November 21, 2019. The offering is subject to market and other … Get the hottest stocks to trade every day before the market opens 100% ‎free. PITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it has commenced an underwritten public offering of shares of common stock. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. View the latest NBSE stock quote and chart on MSN Money. Neubase Therapeutics Inc (NBSE) stock started the day with a 3.09% gain on Wednesday, April 21, 2021, but in the after-hours session, it dropped 9.17% to close at $5.45 per share. View real-time stock prices and stock quotes for a full financial overview. NeuBase Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. NeuBase Therapeutics, Inc. (NBSE), a biotechnology company accelerating the genetic revolution with a new class of precisi... NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock NeuBase Therapeutics, Inc. Stock analysis for NeuBase Therapeutics Inc (OHRP) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest NeuBase Therapeutics, Inc. (NBSE) stock discussions in Yahoo Finance's forum. On average, Wall Street analysts predict that . NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock Yahoo Canada Sports 4/22/2021 NBSE - NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Share your opinion and gain insight from other stock traders and investors. It engages in the development of drugs for patients with genetic neurological disorder. PITTSBURGH, April 27, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today that it has commenced an underwritten public offering of shares of common stock. With the stocks previous close at 8.14 this would indicate that there is a potential upside of 92.5%. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. NeuBase Therapeutics overview. Click here now. NeuBase Therapeutics Inc. (NASDAQ:NBSE) changes shares on Tuesday trading session, with a change of -3.94% or -$0.34 shares. 07:40 AM ET. NeuBase Therapeutics with ticker code (NBSE) have now 6 analysts covering the stock. Stock analysis for NeuBase Therapeutics Inc (NBSE:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. NeuBase Therapeutics Inc stock rating and analysis - : a summary of key financial strength and profitability metrics. The young Pittsburgh-based biotech firm intends to use the capital for general corporate purposes, working capital and development of its product candidates and pipeline expansion. Find the latest NeuBase Therapeutics, Inc. (NBSE) stock quote, history, news and other vital information to help you with your stock trading and investing. NeuBase Therapeutics, Inc. Common Stock, also called NeuBase Therapeutics, is a biotechnology company. NeuBase Therapeutics General Information Description. In addition, NeuBase intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold … NeuBase Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. For financial reporting, their fiscal year ends on September 30th. PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the … Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. The shares fell to a low of $5.42 before closing at $5.70. I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. NeuBase Therapeutics's share price could stay at $17.00 by Feb 12, 2022. Nakae covers the Healthcare sector, … Get NeuBase Therapeutics Inc (NBSE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The new note on the price target was released on June 16, 2020, representing the official price target for NeuBase Therapeutics Inc. stock. NeuBase Therapeutics, Inc. is a biotechnology company. NeuBase Therapeutics, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. The firms pipelines include Huntington’s Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. This is 1.96% more than the trading day before Thursday, 20th May 2021. NeuBase Therapeutics, Inc. 700 Technology Drive Pittsburgh, PA 15219 T: 646-450-1790 View the latest NeuBase Therapeutics Inc. (NBSE) stock price, news, historical charts, analyst ratings and financial information from WSJ. The stock spiked 3.24% in intraday trading to $8.94- this Thursday, Jan 21, hitting a weekly high. According to Zacks, “NeuBase Therapeutics Inc. is a biotechnology company. NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. ET on May 19 Oppenheimer Rare & Orphan Disease Summit presentation on May 21 PITTSBURGH, May 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the … Find out more about how you can short NeuBase Therapeutics stock. NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares. Earnings for NeuBase Therapeutics are expected to decrease in the coming year, from ($1.03) to ($1.04) per share. The range between the high target price and low target price is between 18 and 13 calculating the average target price we see 15.67. Get Free Email Updates. Chardan Capital analyst Keay Nakae reiterated a Buy rating on NeuBase Therapeutics (NBSE – Research Report) yesterday and set a price target of $18.00.The company’s shares closed last Monday at $4.95, close to its 52-week low of $4.51. 4 of the analysts rate the stock as a “Buy”. Intraday shares traded counted 4.2 million, which was -1330.02% … 4 Wall Street analysts have issued ratings and price targets for NeuBase Therapeutics in the last 12 months. NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a … The company’s stock price has collected -5.21% of loss in the last five trading sessions. NeuBase Therapeutics is not the only stock insiders are buying. NeuBase Therapeutics currently has 4 buy ratings from Wall Street analysts. Wall Street Stock Market & Finance report, prediction for the future: You'll find the NeuBase Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data NeuBase Therapeutics's NBSE shares and potentially its market environment have been in bearish … The stock traded as high as $12.47 and last traded at $11.69. Chardan Capital analyst Keay Nakae reiterated a Buy rating on NeuBase Therapeutics (NBSE – Research Report) yesterday and set a price target of $18.00.The company’s shares closed last Monday at $4.95, close to its 52-week low of $4.51. NeuBase Therapeutics Inc. [NASDAQ: NBSE] loss -5.00% on the last trading session, reaching $5.70 price per share at the time. Insider trades for Neubase Therapeutics, Inc. (NBSE). NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a PRIVATE Updated May 19, 2021 8:00 PM NBSE 5.01 0.20 (3.84%). Neubase Therapeutics Inc Stock Signals NASDAQ:NBSE Latest Data & Signals Issued. Share your opinion and gain insight from other stock traders and investors. Rhumbline Advisers grew its stake in shares of […] Find real-time NBSE - NeuBase Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Get the latest NeuBase Therapeutics, Inc. NBSE detailed stock quotes, stock … Approximately 418,000 shares changed hands during trading, an increase of 0% from the average daily volume of 417,293 shares. In addition, NeuBase has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public … The company report on April 22, 2021 that NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock.. Get the hottest stocks to trade every day before the market opens 100% free. View NeuBase Therapeutics, Inc. NBSE investment & stock information. Top investors of Neubase Therapeutics Ord stock. Shares of the NeuBase Therapeutics, Inc. stock were declining in yesterday’s aftermarket trading session after the spread of the news that Neubase stock announced the proposed public offering of its common stock.NBSE stock price saw a downtrend of 9.17% to drop at $5.45 a share in the late hours of Wednesday on April 21, 2021. Chardan Capital analyst Keay Nakae reiterated a Buy rating on NeuBase Therapeutics (NBSE) yesterday and set a price target of $18.00. Find out more about how you can short NeuBase Therapeutics stock. At the end of the trading day, the stock’s price was $6.46, reflecting an intraday gain of 9.68% or $0.57. Free forex prices, toplists, indices and lots more. Only 28.98% of the stock of NeuBase Therapeutics is held by institutions. Insiders at NeuBase Therapeutics Have Bought Stock Recently . In a report issued on March 11, RBC Capital also maintained a Buy rating on the stock with a $17.00 price target. NeuBase Therapeutics Inc. (NASDAQ:NBSE) went up by 12.67% from its latest closing price compared to the recent 1-year high of $11.78. 07:40 AM ET. NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. It is engaged in developing antisense therapies to address genetic diseases. The stock has a consensus analyst rating of "Buy." NBSE stock quote, chart and news. NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021. NeuBase Therapeutics found using ticker (NBSE) now have 6 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. NeuBase Therapeutics’ market cap is currently $170.5M and has a P/E ratio of -6.50. Neubase Therapeutics Inc Stock Price (Quote) NASDAQ:NBSE $5.21 (1.96% ) Friday, 21st May 2021 Range Low Price High Price Comment; 30 days: $4.51: $6.60: Friday, 21st May 2021 NBSE stock ended at $5.21. NeuBase Therapeutics, Inc ... NeuBase intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock … After the session, the Healthcare sector daily volume shifted […] Post-Market 0.00 (0.00%) Analysts have given the company’s stock an average 52-week price target of $16.75, forecast between a low of $15 and high of $18. NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer. Over the last three months, we've seen significant insider buying at NeuBase Therapeutics. A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. NeuBase Therapeutics Company Profile. Prelude Capital Management LLC bought a new stake in shares of NeuBase Therapeutics, Inc. (NASDAQ:NBSE) in the 4th quarter, Holdings Channel reports. NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. Furthermore, NeuBase Therapeutics, Inc. (NBSE)’s beta value is 0.08, and its average true range (ATR) is 0.41. Insider Ownership. NeuBase Therapeutics (NASDAQ:NBSE) prices an underwritten public offering of 8M shares of its common stock, at a price to the public of $5.00 per share; gross proceeds $40M. PITTSBURGH, March 16, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today an oral presentation at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference being held … The word on The Street in general, suggests a Strong Buy analyst consensus rating for NeuBase Therapeutics with a $17.33 average price target, representing a 103.6% upside. What it means for NeuBase Therapeutics PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the … Real time NeuBase Therapeutics, Inc. (NBSE) stock price quote, stock graph, news & analysis. Get the latest Neubase Therapeutics, Inc. NBSE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. NeuBase Therapeutics (NASDAQ:NBSE) trades 6.7% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to … March 16, 2021 - 8:00 am. 2021-05-21 Signal in Stochastic changed from bullish to bullish weakening.The stochastic indicator is in the upper part of the neutral territory and it falls. NeuBase Therapeutics shares were trading slightly higher after the biotechnology company announced an underwritten public offering of common stock. PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $5.00 per share. If you had invested in NeuBase Therapeutics stock at $105.00, your return over the last 13 years would have been -93.85%, for an annualized return of -19.3%. Free forex prices, toplists, indices and lots more. NeuBase Therapeutics Starts Share Offering -- Stock Slumps 10% After-Hours 5:44PM ET 4/21/2021 MT Newswires. NBSE was up 0.33% to $6.02 per share on Thursday afternoon. This was due to a glowing note about the biotech from one of … NeuBase Therapeutics, Inc is primarely in the business of pharmaceutical preparations. Get the latest Neubase Therapeutics Inc (NBSE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Wednesday, August 10, 2016 PITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it has commenced an underwritten public offering of shares of common stock. In depth view into NBSE (NeuBase Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. NeuBase Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. Several other institutional investors have also modified their holdings of NBSE. The demand for shares of the company looks higher than the supply. The last trading period has seen NeuBase Therapeutics Inc. (NBSE) move -49.88% and 19.19% from the stock’s 52-week high and 52-week low prices respectively. The daily trading volume for NeuBase Therapeutics Inc. (NASDAQ:NBSE) over the last session is 1.07 million shares. Download as csv Download as Excel. NeuBase Therapeutics Inc. said its public offering generated net proceeds of $46 million. Dive deeper with interactive charts and top stories of NEUBASE THERAPEUTICS, INC.. Get NeuBase Therapeutics, Inc.'s stock price today.
Statewide Temperature Map, Www Concursolutions Nui Sign In Forgot Password, Sydney Aquarium Voucher, Stergiou Fifa 21 Potential, Corpse Party: Blood Covered Repeated Fear Walkthrough, Hotel Holiday Barcelona, Carlos Tevez Wife Mariela, Venum Classic Boxing Gloves, Nokia Edge 2020 Price In Uae, Abarth Punto Alloy Wheels,